Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1CNS 1

Conditions

Lung Neoplasms 76Leukemia, Myeloid, Acute 71Prostatic Neoplasms 67Neoplasm Metastasis 56Carcinoma, Non-Small-Cell Lung 56Breast Neoplasms 45Multiple Myeloma 44Colorectal Neoplasms 41Pancreatic Neoplasms 37Myelodysplastic Syndromes 35Carcinoma, Renal Cell 33Ovarian Neoplasms 31Melanoma 31Leukemia, Lymphocytic, Chronic, B-Cell 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Glioblastoma 27Triple Negative Breast Neoplasms 26Lymphoma, Large B-Cell, Diffuse 26Urinary Bladder Neoplasms 24Lymphoma 23Burkitt Lymphoma 22Squamous Cell Carcinoma of Head and Neck 21Glioma 20Fallopian Tube Neoplasms 20Carcinoma, Hepatocellular 18Mouth Neoplasms 17Leukemia, Biphenotypic, Acute 17Brain Neoplasms 17Sarcoma 16Oropharyngeal Neoplasms 16

Interventions

afamelanotide 2Specimen Handling 1Nivolumab 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Xeroderma Pigmentosum × Specimen Handling × Clear all
NCT04500548 2025-09-10

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

National Cancer Institute (NCI)

Phase 1 Withdrawn
CNSGastrointestinalLymphoidOther hematologic neoplasm

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Lymphoma, Neuroblastoma, Xeroderma Pigmentosum, Central Nervous System Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡